Trial Profile
A Randomized, Double-blind Placebo Controlled, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 After Single Intravenous Administration in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Efepoetin alfa (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors Genexine
- 28 Jan 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Nov 2014 New trial record